IFG Advisory’s Neurocrine Biosciences NBIX Stock Holding History

IFG Advisory’s Portfolio NBIX Stock Details NBIX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-2,506	Closed	-$240K	–	508
2021 Q3	$240K	Buy	2,506 +33	+1%	+$3.12K	0.03%	433
2021 Q2	$240K	Buy	+2,473	New	+$237K	0.03%	424
2020 Q4	–	Sell	-2,264	Closed	-$217K	–	455
2020 Q3	$217K	Buy	2,264 +35	+2%	+$4.05K	0.04%	378
2020 Q2	$271K	Sell	2,229 -100	-4%	-$11.1K	0.05%	323
2020 Q1	$201K	Sell	2,329 -2,278	-49%	-$223K	0.04%	343
2019 Q4	$495K	Buy	+4,607	New	+$482K	0.09%	236

Other funds holding NBIX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

EVM

Eaton Vance Management Boston, Massachusetts $67.5B AUM 11.44% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

IFG Advisory's NBIX Position: Q4 2021 in Review

IFG Advisory sold out of Neurocrine Biosciences (NBIX) in Q4 2021, closing a stake of 2,506 shares — an estimated $240K sold.

IFG Advisory first reported a position in NBIX in Q4 2019 and held it in 6 quarters. The position peaked at $495K in Q4 2019. 405 funds tracked by Wall St. Rank hold NBIX as of Q4 2021.

IFG Advisory reported no remaining Neurocrine Biosciences position as of Q4 2021 after selling out during the quarter.
IFG Advisory sold 2,506 Neurocrine Biosciences shares in Q4 2021, an estimated $240K.
IFG Advisory first reported a position in Neurocrine Biosciences in Q4 2019 and held it in 6 quarters.
IFG Advisory's Neurocrine Biosciences position peaked at $495K in Q4 2019.
405 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q4 2021.

Based on IFG Advisory's 13F filing for Q4 2021, filed 14 Feb 2022.